{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:51:34Z","timestamp":1785855094638,"version":"3.56.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2021-03420"],"award-info":[{"award-number":["2021-03420"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Karolinska Institutet Doctoral funding","award":["2020-01096"],"award-info":[{"award-number":["2020-01096"]}]},{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","award":["2015.0291"],"award-info":[{"award-number":["2015.0291"]}],"id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007232","name":"Radiumhemmets Forskningsfonder","doi-asserted-by":"publisher","award":["231362"],"award-info":[{"award-number":["231362"]}],"id":[{"id":"10.13039\/501100007232","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Platinum resistance remains a major therapeutic challenge in ovarian cancer (OC) and is one of the main causes leading to disease relapse and mortality. Although PARP inhibitors have improved outcomes for a subset of patients, most women continue to rely on platinum-taxol based chemotherapy and ultimately develop recurrent, treatment-resistant disease with limited further therapy options. Therefore, there is a critical need to identify actionable, patient-specific vulnerabilities that would help as an alternative for chemoresistant patients. To identify such therapeutic opportunities, we established 35 patient-derived models from 22 OC patients, representing seven OC subtypes and preserving key molecular features of individual patients. High-throughput drug profiling across a library of 528 oncology-focused compounds generated over 29,000 drug response measurements, revealing inter-patient heterogeneity and sensitivity patterns. Among these, a subset of models exhibited a pronounced dependency on the anti-apoptotic protein Bcl-xL with minimal effects observed on patient-derived fibroblasts and healthy bone marrow, suggesting a therapeutic window. Proteomics-based comparison of Bcl-xL-sensitive and -resistant subclones identified activation of NOTCH signaling as a determinant to reduced response to Bcl-xL inhibition. Blocking of NOTCH signaling with gamma-secretase inhibitors restored sensitivity to Bcl-xL targeting and resensitized resistant cells to Carboplatin, resulting in sustained cytotoxicity in long-term washout assays and ex vivo cultures. Similar effects were observed with both Bcl-xL protein degrader and small molecule inhibitor, supporting robust targeting of Bcl-xL through different modalities. Together, these findings define a NOTCH-modulated Bcl-xL survival axis as a therapeutic vulnerability in platinum resistant OC. More broadly, this study demonstrates how translational drug profiling of physiologically relevant disease models can generate insights with clinical potential and provide precision oncology framework for identifying rational combination strategies to overcome chemoresistance.<\/jats:p>","DOI":"10.1038\/s41698-026-01628-2","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:36:05Z","timestamp":1785843365000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Functional profiling of ovarian cancer models reveals Bcl-xL\/NOTCH targeting to overcome resistance"],"prefix":"10.1038","volume":"10","author":[{"given":"Greta","family":"Gudoityte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olena","family":"Berkovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas M.","family":"Orre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Moussaud-Lamodi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecka","family":"Bergstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Lindberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Haraldsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha Bou","family":"Nafeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9line","family":"Louhaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olli","family":"Kallioniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefin","family":"Fernebro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrika","family":"Joneborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brinton","family":"Seashore-Ludlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"1628_CR1","first-page":"7","volume":"72","author":"BS Chhikara","year":"2022","unstructured":"Chhikara, B. S. Parang, 1* Keykavous, & 2*. Global Cancer Statistics 2022. Trends Projection Anal. 72, 7\u201333 (2022).","journal-title":"Trends Projection Anal."},{"key":"1628_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.soncn.2019.02.001","volume":"35","author":"C Stewart","year":"2019","unstructured":"Stewart, C., Ralyea, C. & Lockwood, S. Ovarian cancer: an integrated review. Semin. Oncol. Nurs. 35, 151\u2013156 (2019).","journal-title":"Semin. Oncol. Nurs."},{"key":"1628_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3390\/biomedicines10010077","volume":"10","author":"MP Garrido","year":"2021","unstructured":"Garrido, M. P. et al. Current treatments and new possible complementary therapies for epithelial ovarian cancer. Biomedicines 10, 77 (2021).","journal-title":"Biomedicines"},{"key":"1628_CR4","doi-asserted-by":"publisher","first-page":"175883592211480","DOI":"10.1177\/17588359221148024","volume":"15","author":"M-J Devlin","year":"2023","unstructured":"Devlin, M.-J. & Miller, R. E. Disparity in the era of personalized medicine for epithelial ovarian cancer. Therapeutic Adv. Med. Oncol. 15, 17588359221148024 (2023).","journal-title":"Therapeutic Adv. Med. Oncol."},{"key":"1628_CR5","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.annonc.2021.02.015","volume":"32","author":"T Baert","year":"2021","unstructured":"Baert, T. et al. The systemic treatment of recurrent ovarian cancer revisited. Ann. Oncol. 32, 710\u2013725 (2021).","journal-title":"Ann. Oncol."},{"key":"1628_CR6","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.21037\/gs-20-325","volume":"9","author":"S Garzon","year":"2020","unstructured":"Garzon, S. et al. Secondary and tertiary ovarian cancer recurrence: What is the best management? Gland Surg. 9, 1118\u20131129 (2020).","journal-title":"Gland Surg."},{"key":"1628_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216057","volume":"555","author":"RL Hollis","year":"2023","unstructured":"Hollis, R. L. Molecular characteristics and clinical behaviour of epithelial ovarian cancers. Cancer Lett. 555, 216057 (2023).","journal-title":"Cancer Lett."},{"key":"1628_CR8","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1177\/1758834017714993","volume":"9","author":"RT Neff","year":"2017","unstructured":"Neff, R. T., Senter, L. & Salani, R. BRCA mutation in ovarian cancer: testing, implications and treatment considerations. Therapeutic Adv. Med. Oncol. 9, 519\u2013531 (2017).","journal-title":"Therapeutic Adv. Med. Oncol."},{"key":"1628_CR9","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1136\/ijgc-2019-000832","volume":"30","author":"IA Voutsadakis","year":"2020","unstructured":"Voutsadakis, I. A. Low-grade serous ovarian carcinoma: an evolution toward targeted therapy. Int. J. Gynecologic Cancer 30, 1619\u20131626 (2020).","journal-title":"Int. J. Gynecologic Cancer"},{"key":"1628_CR10","first-page":"280","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux, S., Braunstein, M. & Oza, A. M. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA: A Cancer J. Clin. 69, 280\u2013304 (2019).","journal-title":"CA: A Cancer J. Clin."},{"key":"1628_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3126","volume":"4","author":"S Domcke","year":"2013","unstructured":"Domcke, S., Sinha, R., Levine, D. A., Sander, C. & Schultz, N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun. 4, 2126 (2013).","journal-title":"Nat. Commun."},{"key":"1628_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00952-5","volume":"13","author":"BM Barnes","year":"2021","unstructured":"Barnes, B. M. et al. Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes. Genome Med. 13, 140 (2021).","journal-title":"Genome Med."},{"key":"1628_CR13","doi-asserted-by":"publisher","first-page":"1104514","DOI":"10.3389\/fcell.2023.1104514","volume":"11","author":"A McCabe","year":"2023","unstructured":"McCabe, A., Zaheed, O., McDade, S. S. & Dean, K. Investigating the suitability of in vitro cell lines as models for the major subtypes of epithelial ovarian cancer. Front. Cell Dev. Biol. 11, 1104514 (2023).","journal-title":"Front. Cell Dev. Biol."},{"key":"1628_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ccell.2021.12.004","volume":"40","author":"A Letai","year":"2021","unstructured":"Letai, A., Bhola, P. & Welm, A. L. Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations. Cancer Cell 40, 26\u201335 (2021).","journal-title":"Cancer Cell"},{"key":"1628_CR15","doi-asserted-by":"publisher","first-page":"912641","DOI":"10.3389\/fmed.2022.912641","volume":"9","author":"GC Napoli","year":"2022","unstructured":"Napoli, G. C., Figg, W. D. & Chau, C. H. Functional drug screening in the era of precision medicine. Front. Med. 9, 912641 (2022).","journal-title":"Front. Med."},{"key":"1628_CR16","doi-asserted-by":"publisher","first-page":"108086","DOI":"10.1016\/j.celrep.2020.108086","volume":"32","author":"RJ Yamulla","year":"2020","unstructured":"Yamulla, R. J., Nalubola, S., Flesken-Nikitin, A., Nikitin, A. Y. & Schimenti, J. C. Most commonly mutated genes in high-grade serous ovarian carcinoma are nonessential for ovarian surface epithelial stem cell transformation. Cell Rep. 32, 108086 (2020).","journal-title":"Cell Rep."},{"key":"1628_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/srep29506","volume":"6","author":"A George","year":"2016","unstructured":"George, A. et al. Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients. Sci. Rep. 6, 29506 (2016).","journal-title":"Sci. Rep."},{"key":"1628_CR18","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1158\/0008-5472.CAN-19-1991","volume":"80","author":"CL Moyer","year":"2020","unstructured":"Moyer, C. L. et al. Rare BRIP1 missense alleles confer risk for ovarian and breast cancer. Cancer Res. 80, 857\u2013867 (2020).","journal-title":"Cancer Res."},{"key":"1628_CR19","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s10038-019-0680-7","volume":"65","author":"B Janssen","year":"2020","unstructured":"Janssen, B., Bellis, S., Koller, T., Tischkowitz, M. & Liau, S.-S. A systematic review of predicted pathogenic PALB2 variants: an analysis of mutational overlap between epithelial cancers. J. Hum. Genet. 65, 199\u2013205 (2020).","journal-title":"J. Hum. Genet."},{"key":"1628_CR20","doi-asserted-by":"crossref","unstructured":"Nakamura, K. et al. Olaparib monotherapy for BRIP1-mutated high-grade serous endometrial cancer. JCO Precision Oncol. 4, PO.19.00368 (2020).","DOI":"10.1200\/PO.19.00368"},{"key":"1628_CR21","doi-asserted-by":"publisher","first-page":"880643","DOI":"10.3389\/fonc.2022.880643","volume":"12","author":"N Mekonnen","year":"2022","unstructured":"Mekonnen, N., Yang, H. & Shin, Y. K. Homologous recombination deficiency in ovarian, breast, colorectal, pancreatic, non-small cell lung and prostate cancers, and the mechanisms of resistance to PARP inhibitors. Front. Oncol. 12, 880643 (2022).","journal-title":"Front. Oncol."},{"key":"1628_CR22","unstructured":"Exome Sequencing Landscape Analysis in Ovarian Clear Cell Carcinoma Shed Light on Key Chromosomal Regions and Mutation Gene Networks."},{"key":"1628_CR23","doi-asserted-by":"publisher","first-page":"662","DOI":"10.12688\/f1000research.24808.2","volume":"9","author":"NA Parker","year":"2020","unstructured":"Parker, N. A., Al-Obaidi, A. & Deutsch, J. M. SMARCB1\/INI1-deficient tumors of adulthood. F1000Res 9, 662 (2020).","journal-title":"F1000Res"},{"key":"1628_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/1093526617749671","volume":"21","author":"BR Pawel","year":"2018","unstructured":"Pawel, B. R. SMARCB1-deficient tumors of childhood: a practical guide. Pediatr. Dev. Pathol. 21, 6\u201328 (2018).","journal-title":"Pediatr. Dev. Pathol."},{"key":"1628_CR25","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/s41379-019-0446-y","volume":"33","author":"MB Heskett","year":"2020","unstructured":"Heskett, M. B. et al. Multiregion exome sequencing of ovarian immature teratomas reveals 2N near-diploid genomes, paucity of somatic mutations, and extensive allelic imbalances shared across mature, immature, and disseminated components. Mod. Pathol. 33, 1193\u20131206 (2020).","journal-title":"Mod. Pathol."},{"key":"1628_CR26","doi-asserted-by":"publisher","unstructured":"Gudoityte, G. et al. Systematic profiling of cancer-fibroblast interactions reveals drug combinations in ovarian cancer. Mol. Oncol. https:\/\/doi.org\/10.1002\/1878-0261.70051 (2025).","DOI":"10.1002\/1878-0261.70051"},{"key":"1628_CR27","doi-asserted-by":"publisher","unstructured":"Murum\u00e4gi, A. et al. Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma. Br. J. Cancer 1\u201313 https:\/\/doi.org\/10.1038\/s41416-022-02067-z (2022).","DOI":"10.1038\/s41416-022-02067-z"},{"key":"1628_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00528-7","volume":"8","author":"N Struyf","year":"2024","unstructured":"Struyf, N. et al. Delineating functional and molecular impact of ex vivo sample handling in precision medicine. npj Precis. Oncol. 8, 38 (2024).","journal-title":"npj Precis. Oncol."},{"key":"1628_CR29","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/s43018-023-00599-8","volume":"4","author":"X Zheng","year":"2023","unstructured":"Zheng, X. et al. Single-cell analyses implicate ascites in remodeling the ecosystems of primary and metastatic tumors in ovarian cancer. Nat. Cancer 4, 1138\u20131156 (2023).","journal-title":"Nat. Cancer"},{"key":"1628_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00463-z","volume":"7","author":"E \u00c5kerlund","year":"2023","unstructured":"\u00c5kerlund, E. et al. The drug efficacy testing in 3D cultures platform identifies effective drugs for ovarian cancer patients. npj Precis. Oncol. 7, 111 (2023).","journal-title":"npj Precis. Oncol."},{"key":"1628_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12957-023-03027-4","volume":"21","author":"R Purwar","year":"2023","unstructured":"Purwar, R. et al. Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trials. World J. Surg. Oncol. 21, 157 (2023).","journal-title":"World J. Surg. Oncol."},{"key":"1628_CR32","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","volume":"11","author":"VA Pullarkat","year":"2021","unstructured":"Pullarkat, V. A. et al. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov. 11, 1440\u20131453 (2021).","journal-title":"Cancer Discov."},{"key":"1628_CR33","doi-asserted-by":"publisher","first-page":"S164","DOI":"10.1016\/j.ygyno.2023.06.168","volume":"176","author":"E Stover","year":"2023","unstructured":"Stover, E., Shay, B., Matulonis, U., Meyerson, M. & Brugge, J. Genetic and pharmacologic dependency upon anti-apoptotic proteins BCL-XL and MCL1 in rare subtypes of ovarian cancer (1259). Gynecologic Oncol. 176, S164\u2013S165 (2023).","journal-title":"Gynecologic Oncol."},{"key":"1628_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05963-1","volume":"14","author":"E Valentini","year":"2023","unstructured":"Valentini, E. et al. Bcl-2 family inhibitors sensitize human cancer models to therapy. Cell Death Dis. 14, 441 (2023).","journal-title":"Cell Death Dis."},{"key":"1628_CR35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/09537104.2020.1724276","volume":"32","author":"H Wei","year":"2021","unstructured":"Wei, H. & Harper, M. T. Comparison of putative BH3 mimetics AT-101, HA14-1, sabutoclax and TW-37 with ABT-737 in platelets. Platelets 32, 105\u2013112 (2021).","journal-title":"Platelets"},{"key":"1628_CR36","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nmeth.3853","volume":"13","author":"M Hafner","year":"2016","unstructured":"Hafner, M., Niepel, M., Chung, M. & Sorger, P. K. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat. Methods 13, 521\u2013527 (2016).","journal-title":"Nat. Methods"},{"key":"1628_CR37","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.3346\/jkms.2014.29.11.1464","volume":"29","author":"Y-J Lee","year":"2014","unstructured":"Lee, Y.-J. et al. Knockdown of Bcl-xL enhances growth-inhibiting and apoptosis-inducing effects of resveratrol and clofarabine in malignant mesothelioma H-2452 cells. J. Korean Med. Sci. 29, 1464\u20131472 (2014).","journal-title":"J. Korean Med. Sci."},{"key":"1628_CR38","doi-asserted-by":"publisher","first-page":"27514","DOI":"10.18632\/oncotarget.25518","volume":"9","author":"D Fukagawa","year":"2018","unstructured":"Fukagawa, D. et al. Protein expression patterns in cancer-associated fibroblasts and cells undergoing the epithelial-mesenchymal transition in ovarian cancers. Oncotarget 9, 27514\u201327524 (2018).","journal-title":"Oncotarget"},{"key":"1628_CR39","unstructured":"FSP-1 expression in cancer cells is relevant to long-term oncological outcomes in nonmetastatic colorectal cancer. https:\/\/kjco.org\/journal\/view.php?doi=10.14216\/kjco.22009."},{"key":"1628_CR40","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nmeth.2732","volume":"11","author":"RMM Branca","year":"2014","unstructured":"Branca, R. M. M. et al. HiRIEF LC-MS enables deep proteome coverage and unbiased proteogenomics. Nat. Methods 11, 59\u201362 (2014).","journal-title":"Nat. Methods"},{"key":"1628_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ol.2022.13355","volume":"24","author":"W Shi","year":"2022","unstructured":"Shi, W., Yao, X., Fu, Y. & Wang, Y. Interferon\u2011\u03b1 and its effects on cancer cell apoptosis (review). Oncol. Lett. 24, 1\u20139 (2022).","journal-title":"Oncol. Lett."},{"key":"1628_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-020-00228-x","volume":"8","author":"D Jorgovanovic","year":"2020","unstructured":"Jorgovanovic, D., Song, M., Wang, L. & Zhang, Y. Roles of IFN-\u03b3 in tumor progression and regression: a review. Biomark. Res. 8, 49 (2020).","journal-title":"Biomark. Res."},{"key":"1628_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-017-0055-y","volume":"8","author":"D Trisciuoglio","year":"2017","unstructured":"Trisciuoglio, D. et al. BCL-XL overexpression promotes tumor progression-associated properties. Cell Death Dis. 8, 3216 (2017).","journal-title":"Cell Death Dis."},{"key":"1628_CR44","doi-asserted-by":"publisher","first-page":"11778","DOI":"10.18632\/oncotarget.2634","volume":"5","author":"U Keitel","year":"2014","unstructured":"Keitel, U. et al. Bcl-xL mediates therapeutic resistance of a mesenchymal breast cancer cell subpopulation. Oncotarget 5, 11778\u201311791 (2014).","journal-title":"Oncotarget"},{"key":"1628_CR45","doi-asserted-by":"crossref","unstructured":"Li, Y.-J. et al. Fatty acid oxidation protects cancer cells from apoptosis by increasing mitochondrial membrane lipids. Cell Rep. 39, (2022).","DOI":"10.1016\/j.celrep.2022.110870"},{"key":"1628_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.442","volume":"4","author":"RY-J Huang","year":"2013","unstructured":"Huang, R. Y.-J. et al. An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530). Cell Death Dis. 4, e915 (2013).","journal-title":"Cell Death Dis."},{"key":"1628_CR47","doi-asserted-by":"publisher","first-page":"6835","DOI":"10.3390\/ijms25136835","volume":"25","author":"A Valle-Mendiola","year":"2024","unstructured":"Valle-Mendiola, A. et al. STAT5 is necessary for the metabolic switch induced by IL-2 in cervical cancer cell line SiHa. Int. J. Mol. Sci. 25, 6835 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1628_CR48","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/2049-3002-2-3","volume":"2","author":"N Masson","year":"2014","unstructured":"Masson, N. & Ratcliffe, P. J. Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways. Cancer Metab. 2, 3 (2014).","journal-title":"Cancer Metab."},{"key":"1628_CR49","unstructured":"Notch signaling pathway in cancer: from mechanistic insights to targeted therapies | Signal Transduction and Targeted Therapy. https:\/\/www.nature.com\/articles\/s41392-024-01828-x."},{"key":"1628_CR50","doi-asserted-by":"publisher","first-page":"e608","DOI":"10.1002\/onco.13627","volume":"26","author":"TR McCaw","year":"2021","unstructured":"McCaw, T. R. et al. Gamma secretase inhibitors in cancer: a current perspective on clinical performance. Oncologist 26, e608\u2013e621 (2021).","journal-title":"Oncologist"},{"key":"1628_CR51","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nrd4252","volume":"13","author":"ER Andersson","year":"2014","unstructured":"Andersson, E. R. & Lendahl, U. Therapeutic modulation of Notch signalling\u2014Are we there yet? Nat. Rev. Drug Discov. 13, 357\u2013378 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1628_CR52","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/bjc.2017.495","volume":"118","author":"N Cook","year":"2018","unstructured":"Cook, N. et al. A phase I trial of the \u03b3-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. Br. J. Cancer 118, 793\u2013801 (2018).","journal-title":"Br. J. Cancer"},{"key":"1628_CR53","volume":"6","author":"S Kummar","year":"2025","unstructured":"Kummar, S. et al. Nirogacestat-the pathway to approval of the first treatment for desmoid tumors, a rare disease. Ther. Adv. Rare Dis. 6, 26330040251317546 (2025).","journal-title":"Ther. Adv. Rare Dis."},{"key":"1628_CR54","unstructured":"BCL-XL\u2013targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors | Science Advances. https:\/\/www.science.org\/doi\/10.1126\/sciadv.ado7120."},{"key":"1628_CR55","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1021\/acs.biochem.4c00577","volume":"64","author":"K Berkley","year":"2025","unstructured":"Berkley, K., Zalejski, J., Sharma, N. & Sharma, A. Journey of PROTAC: from bench to clinical trial and beyond. Biochemistry 64, 563\u2013580 (2025).","journal-title":"Biochemistry"},{"key":"1628_CR56","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","volume":"25","author":"S Khan","year":"2019","unstructured":"Khan, S. et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat. Med. 25, 1938\u20131947 (2019).","journal-title":"Nat. Med."},{"key":"1628_CR57","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1158\/1078-0432.CCR-23-0415","volume":"29","author":"C Saygin","year":"2023","unstructured":"Saygin, C. et al. Dual targeting of apoptotic and signaling pathways in T-lineage acute lymphoblastic leukemia. Clin. Cancer Res. 29, 3151\u20133161 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1628_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/or.2022.8293","volume":"47","author":"L Yang","year":"2022","unstructured":"Yang, L. et al. Molecular mechanisms of platinum\u2011based chemotherapy resistance in ovarian cancer (Review). Oncol. Rep. 47, 1\u201311 (2022).","journal-title":"Oncol. Rep."},{"key":"1628_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02281-2","volume":"24","author":"Z Peng","year":"2025","unstructured":"Peng, Z., Lv, X., Sun, H., Zhao, L. & Huang, S. 3D tumor cultures for drug resistance and screening development in clinical applications. Mol. Cancer 24, 93 (2025).","journal-title":"Mol. Cancer"},{"key":"1628_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11415-2","volume":"10","author":"K Yu","year":"2019","unstructured":"Yu, K. et al. Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types. Nat. Commun. 10, 3574 (2019).","journal-title":"Nat. Commun."},{"key":"1628_CR61","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-1535","author":"TK Foo","year":"2022","unstructured":"Foo, T. K. & Xia, B. BRCA1-dependent and independent recruitment of PALB2-BRCA2-RAD51 in the DNA damage response and cancer. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-1535 (2022).","journal-title":"Cancer Res."},{"key":"1628_CR62","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1136\/ijgc-2020-001556","volume":"30","author":"A Pietragalla","year":"2020","unstructured":"Pietragalla, A., Arcieri, M., Marchetti, C., Scambia, G. & Fagotti, A. Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes. Int. J. Gynecol. Cancer 30, 1803\u20131810 (2020).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"1628_CR63","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/ng.3746","volume":"49","author":"X Wang","year":"2017","unstructured":"Wang, X. et al. SMARCB1-mediated SWI\/SNF complex function is essential for enhancer regulation. Nat. Genet 49, 289\u2013295 (2017).","journal-title":"Nat. Genet"},{"key":"1628_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43498-3","volume":"14","author":"NQ Liu","year":"2023","unstructured":"Liu, N. Q. et al. SMARCB1 loss activates patient-specific distal oncogenic enhancers in malignant rhabdoid tumors. Nat. Commun. 14, 7762 (2023).","journal-title":"Nat. Commun."},{"key":"1628_CR65","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/modpathol.2012.175","volume":"26","author":"LM Sullivan","year":"2013","unstructured":"Sullivan, L. M., Folpe, A. L., Pawel, B. R., Judkins, A. R. & Biegel, J. A. Epithelioid sarcoma is associated with a high percentage of SMARCB1 deletions. Mod. Pathol. 26, 385\u2013392 (2013).","journal-title":"Mod. Pathol."},{"key":"1628_CR66","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.18632\/oncotarget.6459","volume":"7","author":"S Fahiminiya","year":"2015","unstructured":"Fahiminiya, S. et al. Molecular analyses reveal close similarities between small cell carcinoma of the ovary, hypercalcemic type and atypical teratoid\/rhabdoid tumor. Oncotarget 7, 1732\u20131740 (2015).","journal-title":"Oncotarget"},{"key":"1628_CR67","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603\u2013607 (2012).","journal-title":"Nature"},{"key":"1628_CR68","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.3390\/ijms24032651","volume":"24","author":"T Zubair","year":"2023","unstructured":"Zubair, T. & Bandyopadhyay, D. Small Molecule EGFR inhibitors as anti-cancer agents: discovery, mechanisms of action, and opportunities. Int. J. Mol. Sci. 24, 2651 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1628_CR69","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/568938","volume":"2010","author":"DR Siwak","year":"2010","unstructured":"Siwak, D. R. et al. Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J. Oncol. 2010, 568938 (2010).","journal-title":"J. Oncol."},{"key":"1628_CR70","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1177\/1078155220931926","volume":"26","author":"RD Harvey","year":"2020","unstructured":"Harvey, R. D., Adams, V. R., Beardslee, T. & Medina, P. Afatinib for the treatment of EGFR mutation-positive NSCLC: a review of clinical findings. J. Oncol. Pharm. Pr. 26, 1461\u20131474 (2020).","journal-title":"J. Oncol. Pharm. Pr."},{"key":"1628_CR71","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1016\/j.ejca.2015.07.041","volume":"51","author":"A Suder","year":"2015","unstructured":"Suder, A. et al. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours. Eur. J. Cancer 51, 2275\u20132284 (2015).","journal-title":"Eur. J. Cancer"},{"key":"1628_CR72","first-page":"573","volume":"4","author":"N Rinne","year":"2021","unstructured":"Rinne, N. et al. Targeting the PI3K\/AKT\/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer. CDR 4, 573\u2013595 (2021).","journal-title":"CDR"},{"key":"1628_CR73","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga, J. et al. Everolimus in postmenopausal hormone-receptor\u2013positive advanced breast cancer. N. Engl. J. Med. 366, 520\u2013529 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1628_CR74","doi-asserted-by":"publisher","first-page":"58489","DOI":"10.21037\/apm-20-2465","volume":"10","author":"Z Ren","year":"2021","unstructured":"Ren, Z. et al. Clinical analysis of everolimus in the treatment of metastatic renal cell carcinoma. Ann. Palliat. Med. 10, 58489\u201358589 (2021).","journal-title":"Ann. Palliat. Med."},{"key":"1628_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03828-z","volume":"12","author":"R Luc\u00e0","year":"2021","unstructured":"Luc\u00e0, R. et al. Inhibition of the mTOR pathway and reprogramming of protein synthesis by MDM4 reduce ovarian cancer metastatic properties. Cell Death Dis. 12, 558 (2021).","journal-title":"Cell Death Dis."},{"key":"1628_CR76","doi-asserted-by":"publisher","first-page":"33064","DOI":"10.18632\/oncotarget.25869","volume":"9","author":"G David-West","year":"2018","unstructured":"David-West, G., Ernlund, A., Gadi, A. & Schneider, R. J. mTORC1\/2 inhibition re-sensitizes platinum-resistant ovarian cancer by disrupting selective translation of DNA damage and survival mRNAs. Oncotarget 9, 33064\u201333076 (2018).","journal-title":"Oncotarget"},{"key":"1628_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3394-2","volume":"17","author":"HS Chon","year":"2017","unstructured":"Chon, H. S. et al. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers. BMC Cancer 17, 407 (2017).","journal-title":"BMC Cancer"},{"key":"1628_CR78","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31\u201346 (2022).","journal-title":"Cancer Discov."},{"key":"1628_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14737140.2025.2449944","volume":"25","author":"M Molica","year":"2025","unstructured":"Molica, M. & Perrone, S. Venetoclax and beyond: new horizons in CLL and AML therapy. Expert Rev. Anticancer Ther. 25, 1\u20134 (2025).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"1628_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.584974","volume":"10","author":"Y Wei","year":"2020","unstructured":"Wei, Y. et al. Targeting Bcl-2 proteins in acute myeloid leukemia. Front. Oncol. 10, 584974 (2020).","journal-title":"Front. Oncol."},{"key":"1628_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-016-0234-y","volume":"9","author":"MN Abed","year":"2016","unstructured":"Abed, M. N., Abdullah, M. I. & Richardson, A. Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells. J. Ovarian Res. 9, 25 (2016).","journal-title":"J. Ovarian Res."},{"key":"1628_CR82","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ame2.12330","volume":"6","author":"Y Wei","year":"2023","unstructured":"Wei, Y. et al. Anti-apoptotic protein BCL-XL as a therapeutic vulnerability in gastric cancer. Anim. Model Exp. Med. 6, 245\u2013254 (2023).","journal-title":"Anim. Model Exp. Med."},{"key":"1628_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110374","volume":"38","author":"P Ramesh","year":"2022","unstructured":"Ramesh, P. et al. BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer. Cell Rep. 38, 110374 (2022).","journal-title":"Cell Rep."},{"key":"1628_CR84","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1038\/s41388-018-0635-z","volume":"38","author":"K Louault","year":"2019","unstructured":"Louault, K. et al. Interactions between cancer-associated fibroblasts and tumor cells promote MCL-1 dependency in estrogen receptor-positive breast cancers. Oncogene 38, 3261\u20133273 (2019).","journal-title":"Oncogene"},{"key":"1628_CR85","doi-asserted-by":"crossref","unstructured":"Fiorcari, S. et al. Notch2 increases the resistance to venetoclax-induced apoptosis in chronic lymphocytic leukemia B cells by inducing Mcl-1. Front. Oncol. 11, (2022).","DOI":"10.3389\/fonc.2021.777587"},{"key":"1628_CR86","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1158\/1535-7163.MCT-10-0372","volume":"9","author":"M Li","year":"2010","unstructured":"Li, M. et al. Combined inhibition of Notch signaling and Bcl-2\/Bcl-xL results in synergistic anti-myeloma effect. Mol. Cancer Ther. 9, 3200\u20133209 (2010).","journal-title":"Mol. Cancer Ther."},{"key":"1628_CR87","doi-asserted-by":"publisher","first-page":"7191","DOI":"10.1158\/1078-0432.CCR-07-0362","volume":"13","author":"J Witham","year":"2007","unstructured":"Witham, J. et al. The Bcl-2\/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin. Cancer Res. 13, 7191\u20137198 (2007).","journal-title":"Clin. Cancer Res."},{"key":"1628_CR88","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1054\/bjoc.1999.0939","volume":"82","author":"PJ Beale","year":"2000","unstructured":"Beale, P. J., Rogers, P., Boxall, F., Sharp, S. Y. & Kelland, L. R. BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma. Br. J. Cancer 82, 436\u2013440 (2000).","journal-title":"Br. J. Cancer"},{"key":"1628_CR89","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","volume":"9","author":"G Zhong","year":"2024","unstructured":"Zhong, G., Chang, X., Xie, W. & Zhou, X. Targeted protein degradation: advances in drug discovery and clinical practice. Sig Transduct. Target Ther. 9, 308 (2024).","journal-title":"Sig Transduct. Target Ther."},{"key":"1628_CR90","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","volume":"171","author":"AC Palmer","year":"2017","unstructured":"Palmer, A. C. & Sorger, P. K. Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. Cell 171, 1678\u20131691.e13 (2017).","journal-title":"Cell"},{"key":"1628_CR91","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1177\/0192623313486315","volume":"42","author":"SA Aguirre","year":"2014","unstructured":"Aguirre, S. A. et al. Intermittent oral coadministration of a gamma secretase inhibitor with dexamethasone mitigates intestinal goblet cell hyperplasia in rats. Toxicol. Pathol. 42, 422\u2013434 (2014).","journal-title":"Toxicol. Pathol."},{"key":"1628_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101027","volume":"14","author":"A Murum\u00e4gi","year":"2021","unstructured":"Murum\u00e4gi, A. et al. STRN-ALK rearranged pediatric malignant peritoneal mesothelioma\u2014functional testing of 527 cancer drugs in patient-derived cancer cells. Transl. Oncol. 14, 101027 (2021).","journal-title":"Transl. Oncol."},{"key":"1628_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.111864","volume":"28","author":"Y Pan","year":"2025","unstructured":"Pan, Y. et al. Functional-proteomics-based investigation of the cellular response to farnesyltransferase inhibition in lung cancer. iScience 28, 111864 (2025).","journal-title":"iScience"},{"key":"1628_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03311-y","volume":"9","author":"Y Zhu","year":"2018","unstructured":"Zhu, Y. et al. Discovery of coding regions in the human genome by integrated proteogenomics analysis workflow. Nat. Commun. 9, 903 (2018).","journal-title":"Nat. Commun."},{"key":"1628_CR95","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","volume":"25","author":"S Khan","year":"2019","unstructured":"Khan, S. et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat. Med 25, 1938\u20131947 (2019).","journal-title":"Nat. Med"},{"key":"1628_CR96","doi-asserted-by":"publisher","first-page":"11463","DOI":"10.1002\/anie.201206231","volume":"51","author":"DL Buckley","year":"2012","unstructured":"Buckley, D. L. et al. Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1\u03b1. Angew. Chem. Int. Ed. Engl. 51, 11463\u201311467 (2012).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"1628_CR97","doi-asserted-by":"crossref","unstructured":"Bricelj, A., Steinebach, C., Kuchta, R., G\u00fctschow, M. & Sosi\u010d, I. E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points. Front. Chem. 9, (2021).","DOI":"10.3389\/fchem.2021.707317"},{"key":"1628_CR98","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1093\/bioinformatics\/btaa138","volume":"36","author":"S Potdar","year":"2020","unstructured":"Potdar, S. et al. Breeze: an integrated quality control and data analysis application for high-throughput drug screening. Bioinformatics 36, 3602\u20133604 (2020).","journal-title":"Bioinformatics"},{"key":"1628_CR99","unstructured":"Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies | Scientific Reports. https:\/\/www.nature.com\/articles\/srep05193."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01628-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01628-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01628-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:03:23Z","timestamp":1785852203000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01628-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":99,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1628"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01628-2","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"26 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"O.K. is a board member and co-founder for Sartar, advisor to the Knut and Alice Wallenberg Foundation, Novo Nordisk Foundation and Sitra. The other authors do not have a competing interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"301"}}